The Swedish BioFINDER Study
The BioFINDER studies are independent and non-overlapping studies that have been initiated with the overarching aims to discover key mechanisms in Alzheimer’s disease, Parkinson’s disease and other neurodegenerative disorders. These studies are designed to develop early and accurate diagnostic tests, identify novel treatment targets and help to understand the links between different pathologies and clinical symptoms.
News articles
More news →-
BioFINDER study: Blood test sharpens Alzheimer’s diagnosis in primary care
LONDON — Primary care physicians’ accuracy in identifying Alzheimer’s as the cause of a patient’s cognitive symptoms rose from 62 to 88 percent once they had a blood test result, according to research presented this week at the Alzheimer’s...
Read more... -
A drop of blood can detect Alzheimer’s – international award
The 2026 Jeffrey L. Morby Prize has been awarded to researchers from Lund University and Washington University for a study published in Nature Medicine. The paper describes a blood test capable of detecting changes in the brain associated with...
Read more...
Recent key publications
More publications →-
1 July, 2026
Plasma eMTBR-tau243 and %p-tau217 for Biological Staging of Alzheimer Disease
-
15 May, 2026
Proteomic signatures of the APOE ε4 and APOE ε2 genetic variants and Alzheimer’s disease
-
9 April, 2026
Trajectories of plasma and CSF MTBR-tau243 and phosphorylated-tau species across the Alzheimer’s disease continuum.
-
31 March, 2026
A deep joint-learning proteomics model for diagnosis of six conditions associated with dementia
BioFINDER on X
@biofinder_study →
🔬 New work publication in Molecular Psychiatry!
In >2,000 BioFINDER participants, we show that CSF p-tau205 tracks Alzheimer’s disease progression and could contribute to biological staging, emerging later than Aβ42/40 and p-tau217 and closer to neocortical tau pathology.
📢 New preprint from BioFINDER, led by @karlssonlinda1!
We trained a deep learning model to generate synthetic tau-PET 3D scans from more accessible data: structural MRI, plasma p-tau217, and age. https://www.medrxiv.org/content/10.64898/2026.05.06.26352540v1
New paper in @GreenJournal! We investigated whether future AD dementia can be predicted in individuals with subjective cognitive decline. We found that plasma p-tau217, cognitive testing, and APOE ε4 status accurately identify those at highest risk. https://www.neurology.org/doi/pdf/10.1212/WNL.0000000000214983
New publication in JAMA Neurology! 🧠
In this study, led by @gesalbla, we developed and validated a plasma-based biological staging model for Alzheimer’s disease using two blood biomarkers: %p-tau217 and eMTBR-tau243.
Plasma eMTBR-tau243 and %p-tau217 for Biological Staging of Alzheimer Disease
This longitudinal study develops and validates a blood plasma–based biological staging model for Alzheimer disease tha...
jamanetwork.com
New paper in Nature Aging led by PhD student @LuLina000147323! We mapped how APOE ε4 and APOE ε2 shape molecular changes in blood and cerebrospinal fluid across Alzheimer’s disease.
Proteomic signatures of the APOE ε4 and APOE ε2 genetic variants and Alzheimer’s disease
Nature Aging - Apolipoprotein E (APOE) is the strongest genetic influence in Alzheimer’s disease (AD). Compared to ...
www.nature.com
New paper in Nature Communications! We mapped trajectories of multiple tau species in plasma & CSF across the AD continuum. Different tau species change at distinct stages: %p-tau217 earliest, MTBR-tau243 later, highlighting stage-specific biology.
🔗
Trajectories of plasma and CSF MTBR-tau243 and phosphorylated-tau species across the Alzheimer’s...
Nature Communications - Plasma and CSF p-tau biomarkers show similar dynamics across Alzheimer’s disease progression, ...
www.nature.com
New publication alert!
Are patients seen in primary care eligible for amyloid-targeting therapies (ATT) for treatment of Alzheimer’s disease? 🧠We evaluated ATT eligibility among patients with cognitive symptoms in primary care in southern Sweden.
Eligibility for amyloid targeting therapies among primary care patients with cognitive symptoms
Alzheimer's Research & Therapy - Alzheimer’s disease (AD) is the most common cause of dementia and a growing hea...
link.springer.com
New publication out in Brain! 📢We developed a data-driven multimodal biomarker framework to characterize a memory clinic cohort based on the presence, extent, and sequence of common pathologies. This framework may support diagnosis and trial selection.
🔗
Biological classification of memory clinic patients
Mastenbroek et al. present a biological framework developed to categorize individuals in a memory clinic cohort based ...
academic.oup.com
New publication out in Brain! 📢
We found that reference proteins Aβ40 and np-tau consistently helped already high-performing fluid biomarkers (e.g., MTBR-tau243 and p-tau variants) to more reliably represent brain Aβ and tau pathology measured by PET.
🔗
Reference proteins to improve Core 1 and Core 2 Alzheimer’s disease CSF and plasma biomarkers
Karlsson et al. show that normalizing Alzheimer’s disease cerebrospinal fluid and plasma biomarkers to reference prote...
academic.oup.com
📢New in The Lancet Neurology!
We validate a two-step blood test for Alzheimer’s disease:
1️⃣ plasma %p-tau217 identifies amyloid-β pathology
2️⃣ plasma eMTBR-tau243 assesses whether AD pathology is causing clinical symptoms
🔗https://www.sciencedirect.com/science/article/pii/S1474442226000293
New BioFINDER preprint!
We formalise the Aβ–tau–neurodegeneration (ATN) framework into a mechanism-based model of AD, enabling us to simulate longitudinal imaging biomarkers and study how disease processes evolve and interact across the AD continuum.
🔗https://www.biorxiv.org/content/10.64898/2026.01.27.701320v1
New paper out in EMBO Mol Med! We use machine learning to predict Aβ-PET burden from fluid biomarkers
Findings:
-Performance R² = 0.79
-CSF Aβ42/Aβ40 most predictive of Aβ plaque presence
-Plasma p-tau217 best for tracking increasing amyloid plaque burden
Prediction of continuous amyloid positron emission tomography with fluid measures of phosphorylated...
EMBO Molecular Medicine - Brain amyloid-β (Aβ) pathology is a core feature of Alzheimer disease (AD) and can be ...
www.embopress.org
🚨Paper Out in @EANeurology!
Systematic Review & Meta-analysis of ALS Fluid Biomarkers
🧵Key findings:
• NfL leads for both diagnosis (AUC 0.81–0.92) & prognosis (HR 2.8–4.3)
• CSF chitinases, p-tau/t-tau: moderate values
• Marked heterogeneity
🔗
Diagnostic and Prognostic Value of Blood and Cerebrospinal Fluid Biomarkers in Amyotrophic Lateral...
Background Reliable biomarkers for amyotrophic lateral sclerosis (ALS) are urgently needed due to diagnostic and prognos...
doi.org
🚨New publication in Alzheimer's & Dementia! In this perspective paper, we discuss whether Aβ blood biomarkers can replace the accepted reference standard, Aβ-PET, for assessing Aβ burden.🔗Full paper:
Complementary utility of plasma biomarkers and Aβ‐PET for diagnosis, risk‐stratification, and...
With the rapid development of blood biomarkers (BBMs) related to amyloid-β (Aβ) pathology in Alzheimer's disease (AD...
alz-journals.onlinelibrary.wiley.com
🚨New publication in Brain Communications!
In this study, we show that microglial cells play a key role in Alzheimer's disease, particularly in regulating changes in soluble tau, based on cell-type-specific genetic evidence.
🔗Full paper:
Cell-weighted polygenic risk scores are associated with β-amyloid and tau biomarkers in Alzheimer’s...
Kumar et al. report distinct cellular effects on measures of β-amyloid and tau. Importantly, they also found cell-l...
academic.oup.com
5⃣ In conclusion, our results support the clinical utility of plasma p-tau217 as stand-alone tool for identifying preclinical AD but adding confirmatory CSF/PET would further improve PPVs as needed in many clinical applications.